This study analyzes an oral supplement of molecular iodine (I), alone and in combination with the neoadjuvant therapy 5-fluorouracil/epirubicin/cyclophosphamide or taxotere/epirubicin (FEC/TE) in women with Early (stage II) and Advanced (stage III) breast cancer. In the Early group, 30 women were treated with I (5 mg/day) or placebo (colored water) for 7-35 days before surgery. For the Advanced group, 30 patients received I or placebo, along with FEC/TE treatment.
View Article and Find Full Text PDF